ClearPoint Neuro director settles 12,417 RSUs
ClearPoint Neuro director Kristine B. Johnson exercised and settled 12,417 restricted stock units into an equal number of common shares on May 19, 2026.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
ClearPoint Neuro director Kristine B. Johnson exercised and settled 12,417 restricted stock units into an equal number of common shares on May 19, 2026. These RSUs were granted on May 22, 2025 and vested on their scheduled vesting date. After the settlement, she directly holds 71,116 shares of ClearPoint Neuro common stock.
Insider Trade Summary
12,417 shares exercised/converted
Exercise
2 txns
Insider
JOHNSON B KRISTINE
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units | 12,417 | $0.00 | $0.00 |
| Exercise | Common Stock | 12,417 | $0.00 | $0.00 |
Holdings After Transaction:
Restricted Stock Units — 0 contracts (Direct);
Common Stock — 71,116 shares (Direct)
Holdings Before and After:
Restricted Stock Units, 12,417 to 0 contracts (Direct);
Common Stock, 58,699 to 71,116 shares (Direct)
Footnotes (1)
- F1. Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 22, 2025, the reporting person was granted 12,417 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2026 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.
Key Figures
RSUs settled: 12,417 units
Shares received: 12,417 shares
Post-transaction holdings: 71,116 shares
+1 more
4 metrics
RSUs settled
12,417 units
Restricted stock units converted to common stock on May 19, 2026
Shares received
12,417 shares
Common stock issued upon RSU settlement
Post-transaction holdings
71,116 shares
Common stock directly held by Kristine B. Johnson after settlement
RSU grant date
May 22, 2025
Grant date for 12,417 restricted stock units
Key Terms
Restricted Stock Units, derivative security, vesting date
3 terms
Restricted Stock Units financial
"Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. common stock."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
derivative security financial
"This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date, reported with a derivative security code."
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
vesting date financial
"This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did ClearPoint Neuro (CLPT) report for Kristine B. Johnson?
ClearPoint Neuro reported that director Kristine B. Johnson settled 12,417 restricted stock units into the same number of common shares. This was a scheduled equity compensation event rather than an open-market purchase or sale, and reflects routine conversion of previously granted RSUs.
Was the ClearPoint Neuro (CLPT) Form 4 a stock purchase or sale?
The Form 4 shows neither an open-market purchase nor a sale. Instead, it reports the exercise and settlement of 12,417 restricted stock units into common stock, a non-cash equity compensation event occurring on the scheduled vesting date of those RSUs.
What were the terms of the 12,417 restricted stock units at ClearPoint Neuro (CLPT)?
The 12,417 restricted stock units were granted on May 22, 2025, each representing a right to receive one share of ClearPoint Neuro common stock. They vested on the earlier of the first anniversary of the grant date or the day before the company’s 2026 annual stockholder meeting.
Does the ClearPoint Neuro (CLPT) Form 4 indicate any remaining derivative or RSU holdings?
The Form 4 indicates that after settlement, the reported block of 12,417 restricted stock units has a remaining balance of zero. The derivative summary in this filing does not list additional outstanding derivative positions, focusing solely on this vesting and settlement event.
AI-generated analysis. How Rhea-AI works. Not financial advice.
